NK Cell Sources for Immunotherapy Research

🔥 A quiet but meaningful leap in cancer immunotherapy🔥 🔬 Scientists from the Chinese Academy of Sciences have unveiled a scalable way to mass-produce natural killer (NK) cells and CAR-NK cells, using CD34+ stem and progenitor cells from cord blood. Why this matters 👇 📍 Moves engineering upstream, at the stem cell stage 📍 Produces millions of uniform NK cells from a single progenitor 📍 Dramatically reduces viral vector use and cost 📍 Demonstrates strong tumour-killing activity in leukemia models In theory, a fraction of one cord blood unit could generate thousands of therapeutic doses. ⚛️ This is not hype. It is manufacturing science meeting immunology, turning personalised therapy into something closer to platform medicine. If CAR-T was the first act, CAR-NK may well be the scalable sequel. 💎 Progress in oncology is rarely loud. But it compounds.

🚀 Next-Gen Cancer Immunotherapy: CAR-NK & Unconventional CAR-T Cells 🔬 CGT is advancing rapidly! While CAR-T cells revolutionized blood cancer treatment, CAR-NK cells and unconventional CAR-T cells (γδ T, iNKT, MAIT) are emerging as next-gen therapies offering improved safety, scalability, and efficacy, particularly for solid tumors. 1️⃣ CAR-NK Cells: Safer, Scalable, & Off-the-Shelf Unlike CAR-T cells, which require patient-specific manufacturing and can cause severe toxicities, CAR-NK cells offer an off-the-shelf, allogeneic alternative with fewer side effects and easier scalability. 🧬 Why CAR-NK Cells? ✅ Lower Toxicity: CAR-T often causes CRS, ICANS, and GvHD, while CAR-NK cells show much lower toxicity. ✅ No GvHD Risk: HLA mismatch isn't a concern with NK cells, enabling universal application. ✅ Immediate Cytotoxicity: CAR-NK cells directly kill tumor cells without needing activation. ✅ Scalable Manufacturing: Produced from cord blood, iPSCs, or NK-92, allowing large-scale production. ✅ Proven efficacy in blood cancers: 73% response rate in CD19-CAR NK trials for B-cell malignancies. 🚨 Challenges & Solutions 🔁 Persistence? Enhancing persistence with IL-15, IL-21, and PD-1 blockade. 🦠 Solid Tumors? Overcoming TME barriers with new combinations of immune checkpoint inhibitors. 🔬 Active Trials: ✔️ CD19-CAR NK (NCT03056339) for blood cancers ✔️ HER2-CAR NK (NCT04319757) for solid tumors 2️⃣ Unconventional CAR-T Cells: Expanding the Immunotherapy Toolbox γδ T, iNKT, and MAIT cells offer unique advantages in tumor targeting, persistence, and immune evasion resistance. 🔥 γδ T Cells: MHC-Independent Tumor Recognition MHC-independent recognition allows γδ T cells to detect tumor stress ligands like MICA/B, enabling them to attack tumors escaping detection from conventional T cells. 📊 Clinical Progress ✔️ CAR-γδ T for glioblastoma (NCT04107142) ✔️ CAR-γδ T for lung cancer (NCT04735471) 🌍 iNKT Cells: Dual NK/T Function for Tumor Attack iNKT cells can bypass MHC limitations and stimulate broad immune responses. 🔬 Clinical Trials ✔️ CAR-iNKT for neuroblastoma (NCT03774654). 🌱 MAIT Cells: Targeting Mucosal Tumors MAIT cells are ideal for mucosal cancers (lung, liver, gut) due to their ability to recognize microbial-derived antigens. 🔬 Research ✔️ MAIT-based CAR therapies for liver cancer (preclinical) 📍 Links to the full texts 1️⃣ The clinical landscape of CAR NK cells: https://lnkd.in/dA7eV5FJ 2️⃣ The clinical landscape of CAR-engineered unconventional T cells: https://lnkd.in/dpbZza2G #CARTCells #CARNK #γδTCells #iNKTCells #MAITCells #CellTherapy #CancerResearch #Immunotherapy

NK cells are hard to make in large quantities. Especially without contaminating feeder cells. But this paper breaks through those limitations: The Problem - NK cells are limited in availability and persistence - That's hindering therapeutic applications and clinical efficacy What the Authors did: - Developed a two-step, feeder-cell-free culture system to differentiate NK cells from cord blood CD34+ HSPCs Differentiation protocol: CD34+ HSPCs -> T lymphoid progenitor cells -> NK cells Key Results: - Successfully generated high-purity (>90% CD3–CD56+) NK cells from ProT cells within 14 days (traditional methods range from 28-100 days) - The NK cells generated express cytotoxic molecules AND activating receptors - but remain in an immature state - Furthermore, the cells performed well, both in vitro and in vivo This is majorly important. It opens up large-scale production of NK cells... While maintaining purity and function. And compared to the traditional 28-100 day production methods of the past? 14 days is a massive step forward. Excited to see how this opens up the doors for more NK therapies to get developed. Kudos to the authors, great work! Anything else you'd add? Drop it in the comments.

Genetically unmodified, but genetically optimized NK cells...how is this possible? Let me explain. --- If you were to infuse your T cells into me, they’d rip me to shreds because, to them, my whole body would be considered “foreign” - not good. This is unfortunate because allogeneic cell therapies provide a method to overcome many of the limitations that are currently plaguing cell therapy: cost, time, manufacturing complexities, patient-to-patient inconsistencies. On the other hand, natural killer (NK) cells recognize targets through antigen-independent means (they do not recognize targets as “foreign”), so completely genetically unmodified allogeneic NK cells can be infused into a patient and pose very little risk of GvHD. However, there is a catch… The benefits of being able to infuse completely genetically unmodified NK cells would be lost if you were to start genetically enhancing them. So, you’re left infusing “naturally occurring” NK cells that may not be very therapeutically potent… Artiva Biotherapeutics’s AlloNK cells are unique in the fact that they are made from umbilical cord blood (UCB)-derived NK cells - but just not any old UCB cells, very special UCB cells. You see, Artiva screens UCB units for two genetic characteristics; the cells need to: i) express the high-affinity variant of the Fc receptor CD16; this will enhance their ability to engage in antibody-dependent cellular cytotoxicity (ADCC), and ii) have a KIR-B haplotype (this is basically a fancy way of saying, “they express a lot of activating receptors”); this makes them more immunologically potent cells, poised for activation. By selecting only the UCB units that are known to harbor NK cells with these genotypes, Artiva ensures that their genetically unmodified AlloNK cells are, at least, genetically (and therapeutically) “optimized”. By co-administering AlloNK cells with disease antigen-specific antibodies, AlloNK cells can recognize their specific targets - via their expression of CD16 - and have a higher likelihood of activation - via their expression of several activating receptors (KIR-B haplotype). 📭 We cover all of this and more in today's issue of our Bio-to-Biotech newsletter. If you find this kind of thing interesting, definitely subscribe! 📨 Subscribe to Bio-to-Biotech here: https://lnkd.in/eTPt4RnS

#CARNKCells #immunotherapy CAR-NK Cells Against Hematologic Malignancies – Preclinical and Clinical Studies Initial studies on CAR-NK cells have focused on hematological malignancies. Anti-CD19 CAR-NKs from various cell sources and signaling domains demonstrated effective cytotoxicity against B-cell malignancies both in vitro and in vivo. Anti-CD19 CAR-NK-92 cells showed strong anti-lymphoma activity against Rituximab and Obinutuzumab-resistant B-cell lymphoma cells, utilizing granule-mediated apoptosis and IFN-γ signaling. They also secreted CCL3, recruiting NK cells, T cells, macrophages, and DCs to the TME. Clinical Studies In a phase I/II trial, anti-CD19 CAR-NK cells showed an objective response in 8 of 11 patients with CD19-positive leukemia or lymphoma. These cells expanded and persisted in patients for at least 12 months, and importantly, did not cause cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD) CAR-NK Cells Against Solid Tumors – Clinical and Preclinical Studies Preclinical Studies CAR-NK cells targeting various solid tumor antigens, such as EGFR, HER2, Mesothelin, EpCAM, EGFRvIII, and PSCA, demonstrated potent cytotoxicity in preclinical studies. Advantages CAR-NK cells offer several advantages over CAR-T cells. They can be derived from various sources, are HLA-independent, and can be used allogeneically without the risk of GvHD. NK cells' innate ability to recognize tumor cells via native receptors makes them resistant to antigen escape. Clinical trials have shown CAR-NK cells have a lower risk of adverse effects like neurotoxicity and CRS compared to CAR-T cells. Their ability to distinguish between healthy and malignant cells reduces off-target toxicity. Additionally, safety mechanisms like the caspase-9-based suicide gene allow controlled elimination of NK cells if necessary. Challenges and Solutions CAR-NK cells face challenges such as limited persistence without cytokine support. Solutions include expressing membrane-bound IL-15, using IL-15 receptor fusion constructs, or genetically engineering NK cells to produce IL-15. Overcoming the immunosuppressive TME involves using decoy-resistant IL-18, dominant-negative TGF-β receptors, or knocking out TGF-β-induced miR-27-5p. Enhancing CAR-NK cell trafficking to tumors involves arming them with chemokine receptors like CCR7 and CXCR2 CAR-NK cells recognize cancer cells via their CAR and activating NK cell receptors. They induce anti-tumor toxicity through granzyme B/perforin secretion and death receptor-mediated killing (FasL, TRAIL), participate in ADCC and activate T cells through cytokine secretion Source: https://lnkd.in/eP85JinG

Adoptive NK cell therapy in AML: progress and challenges Adoptive cell therapy (ACT) using natural killer (NK) cells has emerged as a promising therapeutic strategy for acute myeloid leukemia (AML), addressing challenges such as chemotherapy resistance and high relapse rates. Over the years, clinical trials and studies have explored various sources of NK cells, including ex vivo expanded NK cell lines, CAR-NK cells, peripheral blood-derived NK cells, and umbilical cord blood-derived NK cells. These therapies have demonstrated varying degrees of therapeutic efficacy, ranging from transient anti-leukemia activity to sustained remission in select patient groups. Toxicity profiles have generally shown favorable safety outcomes, with minimal incidence of severe adverse effects such as cytokine release syndrome (CRS) or graft-versus-host disease (GVHD). However, persistent challenges remain, including limited NK cell persistence, relapse, and heterogeneity in patient responses. This review provides a comprehensive analysis of clinical outcomes and toxicity profiles provided from clinical trials, clinical studies and case reports conducted in the last 15 years to judge on the efficacy, safety and applicability of using NK cells for ACT of AML. Our review highlights the significant potential of NK cell-based therapies for AML, while addressing the technical and biological challenges that must be overcome to enhance their efficacy and safety. https://lnkd.in/eZyVTRdv